Skip to main content
Fig. 1 | BMC Anesthesiology

Fig. 1

From: Propofol enhances BCR-ABL TKIs’ inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression

Fig. 1

Propofol is active against CML cells and enhances imatinib’s inhibitory effects. Propofol significantly inhibits proliferation (a), induces apoptosis (b) and increases caspase 3 activities (c) in K562, KBM7 and KU812 cells in a dose-dependent manner. Combination of propofol and imatinib results in significant more proliferation inhibition and apoptosis induction than propofol or imatinib alone in CML cells. Propofol at 5 μM and imatinib at 1 μM were used for combination studies. DMSO (final concentration 0.5%) was used as control. *p < 0.05, compared to control or single drug alone

Back to article page